Endocrine and metabolic link to coronavirus infection
Open Access
- 2 April 2020
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 16 (6), 297-298
- https://doi.org/10.1038/s41574-020-0353-9
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infectionJCI Insight, 2019
- Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study)Current Diabetes Reviews, 2019
- Characterization of ACE and ACE2 Expression within Different Organs of the NOD MouseInternational Journal of Molecular Sciences, 2017
- Fetal betamethasone exposure attenuates angiotensin-(1-7)-Mas receptor expression in the dorsal medulla of adult sheepPeptides, 2013
- ACE2, angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosisBritish Journal of Pharmacology, 2013
- Binding of SARS coronavirus to its receptor damages islets and causes acute diabetesActa Diabetologica, 2009
- Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARSDiabetic Medicine, 2006
- Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic ratsMetabolism, 2005